Executive Order 14297: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients

What does Executive Order 14297 do?

The text directs HHS to set and communicate MFN targets, and HHS to facilitate direct purchasing and assess progress.

Reading the operative provisions of Executive Order 14297

EO 14297 directs HHS to communicate most-favored-nation price targets to drug manufacturers and consider regulatory or enforcement steps if negotiations do not produce the desired results. It seeks to tie some U.S. prices to lower prices paid in other developed countries. The order’s operative text appears in the Federal Register publication of EO 14297. It does not itself impose a uniform legal price on every medicine sold in the United States.

The phrase “most favored nation” describes a policy benchmark, but the comparison depends on which countries, products, dosage forms and payment channels are included. A manufacturer may offer a voluntary price arrangement, while a binding change to federal reimbursement generally requires a separate program authority or regulatory action. The order therefore starts a negotiation and policy process rather than immediately changing the amount a patient pays at the pharmacy counter.

Any later action must be read in the context of Medicare, Medicaid, commercial insurance and federal procurement rules, which are not interchangeable. A lower manufacturer price does not always translate into a lower patient copay if benefit design, rebates or pharmacy costs differ. To evaluate results, compare the final price arrangement, covered population, effective date and patient out-of-pocket cost. An agency announcement about a target is not enough to establish savings for every patient.

The order sets a negotiation pathway and asks HHS to identify next steps, so manufacturers’ responses and later agency measures determine whether it changes prices. If a company accepts a voluntary arrangement, the agreement’s covered products, buyers and timing define its reach. If HHS pursues regulation, notice, statutory authority and judicial review may follow. Patients should look for current formulary and benefit information rather than assume that a target price is already available at the pharmacy.